Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2023 / Articles / Mar / Memorable Mushrooms
Discovery & Development Drug Discovery Small Molecules Research News Small Molecules

Memorable Mushrooms

These fungi have some real nerve (developing properties)

By Rob Coker 03/17/2023 2 min read

Share

With the pharmaceutical industry still eagerly awaiting positive results from ongoing Alzheimer’s drug trials, perhaps the search for an effective – and sustainable – treatment needs to extend into the dark, damp places preferred by fungi. In fact, extracts from the lion’s mane mushroom (Hericium erinaceus) have been used in traditional medicines for centuries, but scientists from the University of Queensland, Australia, and Chungbuk National University and Gachon University, South Korea, are now investigating the compounds for potential applications in Alzheimer’s treatment (1).

Credit: Henk Monster / Wikipedia

Tests have shown that certain compounds from the mushrooms could potentially improve memory in both rats and humans, although scientists have not yet pinpointed the exact compound or combination of compounds. The lion’s mane mushroom contains, in its edible parts, both hericenones and erinacines, which the research team says are linked to brain cell growth and memory improvement. Lead author of the paper, Frédéric Meunier, Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, Australia, said, “Using super-resolution microscopy, we found the mushroom extract and its active components largely increase the size of growth cones, which are particularly important for brain cells to sense their environment and establish new connections with other neurons in the brain.”

Further evidence suggests that the active ingredients could also help brain cells live longer, hence the interest in Alzheimer’s treatment. According to the researchers, a Japanese study from 2009 showed similar results in people aged 50–80 who were diagnosed with mild cognitive impairment (2). Those participants who took lion’s mane mushroom extracts three times per day for 16 weeks exhibited significant improvement in cognitive function compared with a control group. Tests continued after the 16 week intake period and showed a subsequent decline in cognitive function.

Is there a future of lion’s mane compounds in Alzheimer’s treatments? Well, I don’t think there’s mushroom for debate (sorry). 

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. F Meunier et al, ‘Hericerin derivatives activates a pan-neurotrophic pathway in central hippocampal neurons converging to ERK1/2 signaling enhancing spatial memory’,  J Neurochem, [online ahead of print] (2023). DOI: 10.1111/jnc.15767
  2. K Mori et al, ‘Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial’, Phytother Res, 23,3 (2009). PMID: 18844328

About the Author(s)

Rob Coker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and The Medicine Maker.

More Articles by Rob Coker

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.